Navigation Links
Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
Date:2/25/2009

NEW YORK, Feb. 26, 2009 /PRNewswire-FirstCall/ --Forest Laboratories, Inc. (NYSE: FRX) today announced that a complaint filed against the Company by the United States was unsealed in Massachusetts federal court alleging violations of the federal False Claims Act arising from Forest's marketing of its antidepressants Lexapro(R) and Celexa(R). The Complaint alleges that Forest personnel improperly promoted Lexapro and Celexa for off-label pediatric use, and that Forest paid kickbacks to physicians to induce them to prescribe these drugs. The Company understands that eleven states and the District of Columbia have also filed notices of intention to intervene as plaintiffs in the action. The Company had previously disclosed the government investigation in all periodic reports filed with the SEC since 2004. In its Form 10-Q filing for the period ending September 30, 2008, Forest disclosed the government's intention to assert civil claims against Forest under the False Claims Act. Forest is committed to adhering to the highest ethical and legal standards, and off-label promotion and improper payments to medical providers have consistently been against Forest policy. Forest is currently reviewing the complaint and will respond to this action at the appropriate time. In addition, as previously disclosed, Forest is continuing its discussions with the government about the investigation.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
2. Old-Growth Forests Dying Off in U.S. West
3. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
4. Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
5. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
6. Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
7. Forest Laboratories Responds To Unsolicited Mini-Tender Offer
8. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
9. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
10. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
11. Lake Forest, CA: SpeechPhone Launches Handsfree Driving Solution Just in Time to Comply with New Handsfree Driving Laws
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: